General
Preferred name
CLOFAZIMINE
Synonyms
NSC-141046 ()
G-30320 ()
Lamprene ()
G 30320 ()
Clofaziminum ()
Colfazimine ()
Chlofazimine ()
Clofazimine-d7 ()
P&D ID
PD000250
CAS
2030-63-9
Tags
natural product
drug
available
Approved by
FDA
First approval
1986
Drug Status
approved
Max Phase
Phase 4
Drug indication
Antibacterial (tuberculostatic)
Antibacterial (leprostatic)
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
10
Compound Sets
12
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
472.12
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
3
cLogP
7.49
TPSA
42.21
Fraction CSP3
0.11
Chiral centers
0.0
Largest ring
6.0
QED
0.27
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Indication
leprosy
MOA
GK0582 inhibitor
Target
Antineoplastic and Immunosuppressive Antibiotics,Dyes,Phospholipase (e.g. PLA)
Source data
